David Bumcrot
Overview
Explore the profile of David Bumcrot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
3064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramaswami G, Yuva-Aydemir Y, Akerberg B, Matthews B, Williams J, Golczer G, et al.
Sci Rep
. 2024 Apr;
14(1):9346.
PMID: 38654092
No abstract available.
2.
Ramaswami G, Yuva-Aydemir Y, Akerberg B, Matthews B, Williams J, Golczer G, et al.
Sci Rep
. 2024 Jan;
14(1):2153.
PMID: 38272949
Microglia are the resident immune cells in the brain that play a key role in driving neuroinflammation, a hallmark of neurodegenerative disorders. Inducible microglia-like cells have been developed as an...
3.
JMnorm: a novel joint multi-feature normalization method for integrative and comparative epigenomics
Xiang G, Guo Y, Bumcrot D, Sigova A
Nucleic Acids Res
. 2023 Dec;
52(2):e11.
PMID: 38055833
Combinatorial patterns of epigenetic features reflect transcriptional states and functions of genomic regions. While many epigenetic features have correlated relationships, most existing data normalization approaches analyze each feature independently. Such...
4.
Schwartz B, Rajagopal V, Smith C, Cohick E, Whissell G, Gamboa M, et al.
Cells
. 2020 Oct;
9(10).
PMID: 33036387
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging worldwide epidemics, projected to become the leading cause of liver transplants. The strongest genetic risk factor for NAFLD/NASH susceptibility...
5.
Maeder M, Stefanidakis M, Wilson C, Baral R, Barrera L, Bounoutas G, et al.
Nat Med
. 2019 Jan;
25(2):229-233.
PMID: 30664785
Leber congenital amaurosis type 10 is a severe retinal dystrophy caused by mutations in the CEP290 gene. We developed EDIT-101, a candidate genome-editing therapeutic, to remove the aberrant splice donor...
6.
Shen S, Sanchez M, Blomenkamp K, Corcoran E, Marco E, Yudkoff C, et al.
Hum Gene Ther
. 2018 Apr;
29(8):861-873.
PMID: 29641323
Alpha-1 antitrypsin deficiency (AATD) is a hereditary liver disease caused by mutations in the SERPINA1 serine protease inhibitor gene. Most severe patients are homozygous for PiZ alleles (PiZZ; amino acid...
7.
Grondin R, Ai Y, Hardy P, Butt M, Nelson B, Lemmon J, et al.
J Neurosurg
. 2016 May;
126(4):1253-1262.
PMID: 27231974
OBJECTIVE A better understanding of the effects of chronically delivering compounds to the substantia nigra and nearby areas is important for the development of new therapeutic approaches to treat alpha-synucleinopathies,...
8.
Friedland A, Baral R, Singhal P, Loveluck K, Shen S, Sanchez M, et al.
Genome Biol
. 2015 Nov;
16:257.
PMID: 26596280
Background: CRISPR-Cas systems have been broadly embraced as effective tools for genome engineering applications, with most studies to date utilizing the Streptococcus pyogenes Cas9. Here we characterize and manipulate the...
9.
Gori J, Hsu P, Maeder M, Shen S, Welstead G, Bumcrot D
Hum Gene Ther
. 2015 Jun;
26(7):443-51.
PMID: 26068008
Genome editing using the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated 9 (Cas9) technology is revolutionizing the study of gene function and likely will give rise to an entire...
10.
Sehgal A, Chen Q, Gibbings D, Sah D, Bumcrot D
RNA
. 2013 Dec;
20(2):143-9.
PMID: 24355758
Pharmacologic target gene modulation is the primary objective for RNA antagonist strategies and gene therapy. Here we show that mRNAs encoding tissue-specific gene transcripts can be detected in biological fluids...